Prosecution Insights
Last updated: October 04, 2026
Application No. 18/812,872

COMPOUNDS, COMPOSITIONS AND METHODS

Non-Final OA §112
Filed
Aug 22, 2024
Priority
Feb 13, 2019 — provisional 62/805,273 +2 more
Examiner
JACKSON, SHAWQUIA
Art Unit
Tech Center
Assignee
Denali Therapeutics Inc.
OA Round
1 (Non-Final)
78%
Grant Probability
Favorable
1-2
OA Rounds
1m
Est. Remaining
75%
With Interview

Examiner Intelligence

Grants 78% — above average
78%
Career Allowance Rate
1430 granted / 1834 resolved
+18.0% vs TC avg
Minimal -3% lift
Without
With
+-3.3%
Interview Lift
resolved cases with interview
Typical timeline
2y 3m
Avg Prosecution
45 currently pending
Career history
1854
Total Applications
across all art units

Statute-Specific Performance

§101
2.7%
-37.3% vs TC avg
§103
14.9%
-25.1% vs TC avg
§102
18.3%
-21.7% vs TC avg
§112
50.6%
+10.6% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1834 resolved cases

Office Action

§112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION Claims 17-24 are currently pending in the instant application. Applicants have amended claims 17, 18, 21 and 22 and canceled claims 1-16 and 25-31 in an amendment filed on January 6, 2025. Claims 17-22 and 24 are considered allowable and claim 23 is rejected in this Office Action. I. Priority The instant application is a DIV of 17/430,570, filed on August 12, 2021 PAT 12,091,392 which is a 371 of PCT/US2020/017985, filed on February 12, 2020 which claims benefit of US Provisional Application 62/805,273, filed on February 13, 2019. II. Information Disclosure Statement The information disclosure statement (IDS) submitted on January 6, 2025 is in compliance with the provisions of 37 CFR 1.97. Accordingly, the information disclosure statement has been considered by the examiner. III. Rejections Claim Rejections - 35 USC § 112 The following is a quotation of the second paragraph of 35 U.S.C. 112: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claim 23 is rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. The term “enhancing” in claim 23 is a relative term which renders the claim indefinite. The term “enhancing” is not defined by the claim, the specification does not provide a standard for ascertaining the requisite degree, and one of ordinary skill in the art would not be reasonably apprised of the scope of the invention. Applicants are suggested to cancel claim 23 or amend claim 23 by deleting the term “enhancing” to overcome the rejection. ***The closest prior art is Sidrauski, et al. (WO 2017/193030 A1) which teaches compounds such as PNG media_image1.png 100 355 media_image1.png Greyscale but does not teach compounds with the chain PNG media_image2.png 80 118 media_image2.png Greyscale or PNG media_image3.png 66 96 media_image3.png Greyscale as seen in the instant compounds. The claimed compounds are neither taught nor suggester by the prior art. IV. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to Shawquia Jackson whose telephone number is 571-272-9043. The examiner can normally be reached on 7:00 AM-3:30PM. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Adam Milligan can be reached on 571-270-7674. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). /SHAWQUIA JACKSON/ Primary Examiner, Art Unit 1626
Read full office action

Prosecution Timeline

Aug 22, 2024
Application Filed
Aug 12, 2026
Non-Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12747219
COMPOUNDS AND METHODS OF INHIBITING BACTERIAL CHAPERONIN SYSTEMS
3y 5m to grant Granted Sep 29, 2026
Patent 12735390
PYRYLIUM METHOD OF PREPARING PYRIMIDINE CYCLOHEXYL GLUCOCORTICOID RECEPTOR MODULATORS
2y 3m to grant Granted Sep 15, 2026
Patent 12734152
SOLID STATE FORMS OF NIROGACESTAT SALTS
2y 3m to grant Granted Sep 15, 2026
Patent 12729194
COMPOUNDS FOR THE TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS
4y 5m to grant Granted Sep 08, 2026
Patent 12715840
METHOD FOR MANUFACTURING AROMATIC NITRILE COMPOUND
2y 2m to grant Granted Aug 25, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
78%
Grant Probability
75%
With Interview (-3.3%)
2y 3m (~1m remaining)
Median Time to Grant
Low
PTA Risk
Based on 1834 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month